A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): Study protocol for a mixed-methods study

Trials

Volumn 15, Issue 1, 2014, Pages

  Smith, Joanna D ^a   Baillie, Jessica ^a   Baglin, Trevor ^b   Griffiths, Gareth O ^a   Casbard, Angela ^a   Cohen, David ^c   Fitzmaurice, David A ^d   Hood, Kerenza ^a   Rose, Peter ^e   Cohen, Alexander T ^f   Johnson, Miriam ^g   Maraveyas, Anthony ^g   Bell, John ^a   Toone, Harold ^a   Nelson, Annmarie ^a   Noble, Simon I ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLAMORGAN   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e WARWICK HOSPITAL   (United Kingdom)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Cancer associated thrombosis; Deep vein thrombosis; Framework analysis; Low molecular weight heparin; Mixed methods; Palliative care; Pulmonary embolus; Qualitative research; Randomized controlled trial; Venous thromboembolism

Indexed keywords

DALTEPARIN; ENOXAPARIN; TINZAPARIN;

ADVANCED CANCER; ANTICOAGULANT THERAPY; ARTICLE; ATTITUDE TO HEALTH; CANCER ASSOCIATED THROMBOSIS; CLINICAL EFFECTIVENESS; CONSENSUS; COST EFFECTIVENESS ANALYSIS; FEASIBILITY STUDY; HEALTH CARE SURVEY; HUMAN; METASTASIS; MULTICENTER STUDY (TOPIC); PATIENT ATTITUDE; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITATIVE RESEARCH; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELATIVE; SEMI STRUCTURED INTERVIEW; STUDY DESIGN; THROMBOSIS; UNITED KINGDOM;

ANTICOAGULANTS; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEASIBILITY STUDIES; FOCUS GROUPS; GREAT BRITAIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERVIEWS AS TOPIC; NEOPLASMS; QUALITATIVE RESEARCH; RESEARCH DESIGN; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899637608     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-122     Document Type: Article

References (46)

1. Silverstein M, Heit J, Mohr D, Petterson T, O'Fallon W, Melton LI. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998, 158:585-593. 10.1001/archinte.158.6.585, 9521222.
2. White R. The epidemiology of venous thromboembolism. Circulation 2003, 107:I4-I8.
3. Department of Health Report of the Independent Expert Working Group on the Prevention of Venous Thromboembolism in Hospitalised Patients 2007, London: Department of Health, Department of Health.
4. Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010, 102:2-9.
5. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C. British Committee for Standards in Hematology: Guidelines of oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011, 154:311-324. 10.1111/j.1365-2141.2011.08753.x, 21671894.
6. Noble S, Shelley M, Coles B, Williams S, Wilcock A, Johnson M. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 2008, 9:577-584. 10.1016/S1470-2045(08)70149-9, 18510989.
7. Levitan N, Dowlati A, Remick S, Tahsildar H, Sivinski L, Beyth R, Rimm A. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999, 78:285-291. 10.1097/00005792-199909000-00001, 10499070.
8. Sorensen H, Mellemkjaer L, Olsen J, Baron J. Prognosis of cancers associated with venous thromboembolism. New England Med J 2000, 343:1846-1850.
9. Noble S. The challenges of managing cancer related venous thromboembolism in the palliative care setting. Postgrad Med J 2007, 83:671-674. 10.1136/pgmj.2007.061622, 2659959, 17989265.
10. Noble S, Finlay I. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer associated thromboembolism? A qualitative study. Palliat Med 2005, 19:197-201. 10.1191/0269216305pm1008oa, 15920933.
11. Hull R, Pineo G, Brant R, Mah A, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon M, Raskob G., LITE Trial Investigators Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006, 119:1062-1072. 10.1016/j.amjmed.2006.02.022, 17145251, LITE Trial Investigators.
12. Lee A, Levine M, Baker R, Bowden C, Kakkar A, Prins M, Rickles F, Julian J, Haley S, Kovacs M, Gent M., CLOT Investigators Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Med J 2003, 349:146-153. CLOT Investigators.
13. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra J, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002, 162:1729-1735. 10.1001/archinte.162.15.1729, 12153376.
14. Kearon C, Kahn S, Agnelli G, Goldhaber S, Roskob G, Comerota A., Physicians ACoC Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:454-545. Physicians ACoC.
15. Khorana A, Streiff M, Farage D, Mandala M, Debourdeau P, Cajifinger F, Marty M, Falanga A, Lyman G. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009, 27:4919-4926. 10.1200/JCO.2009.22.3214, 2799060, 19720907.
16. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013, 11:56-70. 10.1111/jth.12070, 23217107.
17. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005, 293:715-722. 10.1001/jama.293.6.715, 15701913.
18. Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol) 1999, 11:105-110. 10.1053/clon.1999.9023, 10378636.
19. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007, 110:2339-2346. 10.1002/cncr.23062, 17918266.
20. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002, 100:3484-3488. 10.1182/blood-2002-01-0108, 12393647.
21. Johnson MJ. Problems of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin. Palliat Med 1997, 11:306-312. 10.1177/026921639701100407, 9373582.
22. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR., American College of Chest Physicians Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based Clinical Practice Guidelines. Chest 2012, 141:e419S-e494S. 3278049, 22315268, American College of Chest Physicians.
23. Noble S, Hood K, Finlay I. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients. Palliat Med 2007, 21:473-475. 10.1177/0269216307080816, 17846086.
24. Kakkar A, Kessler C, Goldhaber S, Kovacs M, Spyropolous A, Ortel T, Pabinger I, Huisman M, Bergqvist D, Monreal M, Turpie AG, Francis CW. Dalteparin sodium for the long-term management of venous thromboembolism in cancer patients. The DALTECAN study. J Thromb Haemost 2013, 11:74.
25. Kamphuisen P, Buller H. Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism (Longheva) http://clinicaltrials.gov/show/NCT01164046.
26. Phillips J. select-d: Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism http://www.controlled-trials.com/ISRCTN86712308/.
27. Cosmi B, Legnani C, Iorio A, Pengo V, Ghirarduzzi A, Testa S, Poli D, Tripodi A, Palareti G., PROLONG Investigators (on behalf of FCSE IFoAC) Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. Eur J Vasc Endovasc Surg 2010, 39:356-365. 10.1016/j.ejvs.2009.11.022, 20034816, PROLONG Investigators (on behalf of FCSE IFoAC).
28. Tan M, Mos I, Klok F, Huisman M. Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a systematic review. Br J Haematol 2011, 153:168-178. 10.1111/j.1365-2141.2011.08578.x, 21375522.
29. Barbour R. Doing Focus Groups 2007, Los Angeles: Sage.
30. Krueger R, Casey M. Focus Groups: A Practical Guide for Applied Research 2000, Thousand Oaks, California: Sage, 3.
31. Edwards A, Sivell S, Dundon J, Elwyn G, Evans R, Gaff C, Iredale R, Shaw C, Thornton H, Gray J, Clarke E. Effective risk communication in clinical genetics: a systematic review. Report to: Department of Health; Genetics Research Programme - Health Services Research (Grant HSR03A; ISBN 0-9550975-2-5). Cardiff Centre for Health Sciences Research 2006, Cardiff UK: Cardiff University.
32. Patton M. Qualitative Research and Evaluation Methods 2002, Thousand Oaks, California: Sage Publications.
33. Lewin S, Glenton C, Oxman A. Use of qualitative methods alongside randomized controlled trials of complex healthcare interventions: methodological study. Br Med J 2009, 339:3496.
34. Beanlands H, Horsburgh M, Fox S, Howe A, Locking-Cusolito H, Pare K, Thrasher C. Caregiving by family and friends of adults receiving dialysis. Nephrol Nurs J 2005, 32:621-631.
35. Creswell J. Research Design: Qualitative, Quantitative, and Mixed Methods Approaches 2003, Thousand Oaks, California: Sage Publications.
36. Gillham B. The Research Interview 2000, New York: Continuum.
37. Hussainy S, Marriott J. Recruitment strategies for palliative cancer care patients and carers. Int J Pharm Pract 2009, 17:369-371.
38. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. Analyzing Qualitative Data 1994, London: Routledge, Bryman A, Burgess R.
39. Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N, Filiberti A, Flechtner H, Fleishman S, de Haes J, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376. 10.1093/jnci/85.5.365, 8433390.
40. Herman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5 L). Qual Life Res 2011, 20:1727-1736. 10.1007/s11136-011-9903-x, 3220807, 21479777.
41. National Institute for Health and Care Excellence Guide to the methods of technology appraisal 2013, http://publications.nice.org.uk/guide-to-the-methods-of-technology-appraisal-2013-pmg9, National Institute for Health and Care Excellence.
42. Bruera E, Kuehn N, Miller M, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991, 7:6-9.
43. Watanabe S, Nekolaichuk C, Beaumont C, Johnson L, Myers J, Strasser F. A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J Pain Symptom Manage 2011, 41:456-468. 10.1016/j.jpainsymman.2010.04.020, 20832987.
44. Department of Health Research Governance Framework for Health and Social Care (2nd edn.) 2005, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/139565/dh_4122427.pdf, Department of Health.
45. Welsh Assembly Government Research Governance Framework for Health and Social Care in Wales (2nd ed.) 2009, http://wales.gov.uk/docs/dhss/publications/governance/090929researchen.pdf, Welsh Assembly Government.
46. United Kingdom Data Protection Act 1998 1998, http://www.opsi.gov.uk/acts/acts1998/ukpga_19980029_en_1, United Kingdom.